Brief: Vyne Therapeutics Completes Enrollment In Phase 2A Trial Of FMX114 For Treatment Of Mild-To-Moderate Atopic Dermatitis

YARROW BIOSCIENCE

17/06/2022 13:03

June 17 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2A TRIAL
OF
FMX114 FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS

Source text for Eikon:  ID:nGNX5KdVTH 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))